This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Verona (VRNA) Stock Surges 36% in the Past Month: Here's Why
by Zacks Equity Research
Verona Pharma (VRNA) surges on the recent FDA approval for its lead drug, which is the first inhaled COPD product with a novel mechanism of action in more than 20 years.
Pacira (PCRX) Rises on Proposed Exparel Reimbursement Plan
by Zacks Equity Research
Pacira (PCRX) gains upon the inclusion of Exparel as one of only six qualifying non-opioid drugs to treat postsurgical pain in the proposed reimbursement rule, if adopted.
Inovio (INO) Up as Lead Drug Gets Innovative Medicine Tag in UK
by Zacks Equity Research
Inovio (INO) soars 19% as its lead candidate, INO-3107, receives the innovative medicine tag under the U.K.'s Innovative Licensing and Access Pathway to treat recurrent respiratory papillomatosis.
United Therapeutics (UTHR) Completes Enrolment in IPF Study
by Zacks Equity Research
United Therapeutics' (UTHR) late-stage study is evaluating Tyvaso inhalation solution in IPF patients living outside the United States and Canada.
Indivior (INDV) Down on Dropping Schizophrenia Drug, Cuts '24 View
by Zacks Equity Research
Indivior (INDV) slashes financial guidance for 2024, primarily to reflect adverse sales conditions of its top-selling opioid drug. It will discontinue the sales of its schizophrenia drug.
uniQure (QURE) Soars on New Huntington's Disease Study Data
by Zacks Equity Research
uniQure (QURE) surges 77% on updated positive interim data from 29 treated patients in the ongoing phase I/II studies of investigational gene therapy, AMT-130, for Huntington's disease.
IDEAYA (IDYA) Up on Upbeat Phase II Bladder & Lung Cancer Data
by Zacks Equity Research
IDEAYA (IDYA) gains 15% on positive clinical data from its phase II study evaluating the 30 mg monotherapy expansion dose of IDE397 to treat MTAP-deletion urothelial and NSCLC patients.
Adicet (ACET) Up as Kidney Cancer Drug Gets FDA's Fast Track Tag
by Zacks Equity Research
Adicet (ACET) gains as the FDA grants the Fast Track designation to ADI-270 for the potential treatment of a form of kidney cancer. A phase I study for this indication is set to begin in 2024.
Dianthus (DNTH) Gains 18% in the Past Month: Here's Why
by Zacks Equity Research
Dianthus (DNTH) shares have rallied 18% in the past month on FDA clearance to initiate a phase II study on its lead candidate, DNTH103, to treat an autoimmune indication. Top-line data is expected in 2026.
Roche (RHHBY) Receives FDA Nod for Vabysmo Prefilled Syringe
by Zacks Equity Research
The FDA approves Roche's (RHHBY) Vabysmo prefilled syringe for treating three retinal conditions that can cause blindness.
Apellis' (APLS) Syfovre Boost Sales, Regulatory Setbacks a Woe
by Zacks Equity Research
Apellis' (APLS) revenues rise on the back of the robust uptake of Syfovre for the GA indication. However, the recent regulatory setback in the EU for pegcetacoplan to treat GA is a woe.
Roche's (RHHBY) Combo Therapy Misses Lung Cancer Study Goals
by Zacks Equity Research
Roche (RHHBY) announces that its mid to late-stage lung cancer study evaluating the tiragolumab combination therapy compared with Keytruda fails to meet primary endpoints.
Annovis (ANVS) Up as Its Lead Candidate Meets Goals in PD Study
by Zacks Equity Research
Annovis (ANVS) surges 76% on Jul 2 after meeting the primary and secondary goals with statistical significance in the late-stage PD study of its lead candidate, buntanetap.
Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag
by Zacks Equity Research
Longboard (LBPH) gains 14% as the FDA grants the Breakthrough Therapy designation to its investigational epilepsy treatment candidate, bexicaserin, for patients aged two years or older.
FDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease
by Zacks Equity Research
Per the FDA, Rocket (RCKT) needs to submit additional manufacturing information on Kresladi gene therapy to secure approval for severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder.
Apellis (APLS) Falls on Second Negative CHMP Opinion for GA Drug
by Zacks Equity Research
Apellis (APLS) declines as CHMP issues a second negative opinion for the approval of intravitreal pegcetacoplan to treat GA in the EU. The company plans to seek re-examination of the same.
PTC Therapeutics (PTCT) Down on Negative CHMP Opinion on DMD Drug
by Zacks Equity Research
PTC Therapeutics (PTCT) falls as the EC's advisory committee adopts a negative opinion regarding the renewal of the conditional marketing approval of Translarna to treat nmDMD in the EU.
Cogent (COGT) Up on SUMMIT Study Update Post Positive FDA Meeting
by Zacks Equity Research
Cogent (COGT) announces a positive FDA meeting and alignment on MS2D2, a novel patient-reported outcome measure for the SUMMIT study. The company's shares rise on the news.
Merck's (MRK) New Pneumococcal Jab Capvaxive Gets CDC Panel Vote
by Zacks Equity Research
Merck's (MRK) vaccine, Capvaxive, gets unanimous recommendation by a CDC committee for adults aged 65 years and older for pneumococcal vaccination and those with certain other underlying conditions.
Novo Nordisk's (NVO) Hypertension Drug Study Fails to Meet Goal
by Zacks Equity Research
Novo Nordisk (NVO) declines as a late-stage study of its uncontrolled hypertension and advanced chronic kidney disease candidate, ocedurenone, fails to achieve the primary goal.
CASI Pharmaceuticals (CASI) Up on Buyout Offer for China Business
by Zacks Equity Research
CASI Pharmaceuticals (CASI) gets a proposal letter from its chairman for acquiring its business operations in China. Its shares rise on the news.
Bayer's (BAYRY) AskBio Advances Parkinson Disease Study
by Zacks Equity Research
Bayer's (BAYRY) wholly owned and independently operating subsidiary AskBio started recruitment in the phase II study for Parkinson's disease.
ImmunityBio (IBRX) Gains 17% in the Past Week: Here's Why
by Zacks Equity Research
ImmunityBio (IBRX) rises 17% in the past week as it announces insurance coverage as well as the treatment of the first patients with its newly approved bladder cancer immunotherapy, Anktiva.
Alnylam (ALNY) Soars as Heart Disease Drug Study Meets Goals
by Zacks Equity Research
Alnylam (ALNY) soars as its phase III study, seeking to expand Anvuttra's label to include the treatment of ATTR amyloidosis with cardiomyopathy, achieves primary and all secondary endpoints.
Should You Hold Kodiak Sciences (KOD) Stock in Your Portfolio?
by Zacks Equity Research
Kodiak Sciences (KOD) is evaluating its lead candidate, tarcocimab, in a late-stage study for diabetic retinopathy, which is expected to support a regulatory filing for three eye disease indications.